FDA says generics study is wrong

Share this article:

The FDA is questioning a study that found generics produced abroad included a notable degree of contamination. Bloomberg reports that the regulator is taking on a study presented at a February congressional hearing in which a Brigham & Women's Hospital researcher said he found contaminants among generics made abroad.

The FDA says it will be publishing its own study about generic heart medications, one that used a different testing approach. This approach, reports Bloomberg, did not find contaminants, and the regulator alleges that the Brigham & Women's Hospital researchers contaminated their own samples.

Concern about generics quality has not been hard to find over the last few weeks, particularly when it comes to disputes over drugs manufactured in India.

An FDA spokesperson tells Bloomberg that the regulator expects to publish its findings soon.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.